BACKGROUND: Optic-nerve injury results in impaired transmission of visual signals to central targets and leads to the death of retinal ganglion cells (RGCs) and irreversible vision loss. Therapies with mesenchymal stem cells (MSCs) from different sources have been used experimentally to increase survival and regeneration of RGCs. METHODS: We investigated the efficacy of human umbilical Wharton's jelly-derived MSCs (hWJ-MSCs) and their extracellular vesicles (EVs) in a rat model of optic nerve crush. RESULTS: hWJ-MSCs had a sustained neuroprotective effect on RGCs for 14, 60, and 120 days after optic nerve crush. The same effect was obtained using serum-deprived hWJ-MSCs, whereas transplantation of EVs obtained from those cells was ineffective. Treatment with hWJ-MSCs also promoted axonal regeneration along the optic nerve and reinnervation of visual targets 120 days after crush. CONCLUSIONS: The observations showed that this treatment with human-derived MSCs promoted sustained neuroprotection and regeneration of RGCs after optic nerve injury. These findings highlight the possibility to use cell therapy to preserve neurons and to promote axon regeneration, using a reliable source of human MSCs.
BACKGROUND: Optic-nerve injury results in impaired transmission of visual signals to central targets and leads to the death of retinal ganglion cells (RGCs) and irreversible vision loss. Therapies with mesenchymal stem cells (MSCs) from different sources have been used experimentally to increase survival and regeneration of RGCs. METHODS: We investigated the efficacy of human umbilical Wharton's jelly-derived MSCs (hWJ-MSCs) and their extracellular vesicles (EVs) in a rat model of optic nerve crush. RESULTS: hWJ-MSCs had a sustained neuroprotective effect on RGCs for 14, 60, and 120 days after optic nerve crush. The same effect was obtained using serum-deprived hWJ-MSCs, whereas transplantation of EVs obtained from those cells was ineffective. Treatment with hWJ-MSCs also promoted axonal regeneration along the optic nerve and reinnervation of visual targets 120 days after crush. CONCLUSIONS: The observations showed that this treatment with human-derived MSCs promoted sustained neuroprotection and regeneration of RGCs after optic nerve injury. These findings highlight the possibility to use cell therapy to preserve neurons and to promote axon regeneration, using a reliable source of human MSCs.
Authors: W C Abraham; S E Mason; J Demmer; J M Williams; C L Richardson; W P Tate; P A Lawlor; M Dragunow Journal: Neuroscience Date: 1993-10 Impact factor: 3.590
Authors: Nate Watson; Ryan Divers; Roshan Kedar; Ankur Mehindru; Anuj Mehindru; Mia C Borlongan; Cesar V Borlongan Journal: Cytotherapy Date: 2014-10-18 Impact factor: 5.414
Authors: A Giraldi-Guimarães; R E de Bittencourt-Navarrete; I C C Nascimento; P R Salazar; D Freitas-Campos; R Mendez-Otero Journal: Neuroscience Date: 2004 Impact factor: 3.590
Authors: Raf Donders; Jeroen F J Bogie; Stylianos Ravanidis; Pascal Gervois; Marjan Vanheusden; Raphaël Marée; Marie Schrynemackers; Hubert J M Smeets; Jef Pinxteren; Kristel Gijbels; Sara Walbers; Robert W Mays; Robert Deans; Ludo Van Den Bosch; Piet Stinissen; Ivo Lambrichts; Wilfried Gyselaers; Niels Hellings Journal: Stem Cells Dev Date: 2017-12-21 Impact factor: 3.272
Authors: Allan K N Alencar; Pedro M Pimentel-Coelho; Guilherme C Montes; Marina de M C da Silva; Luiza V P Mendes; Tadeu L Montagnoli; Ananssa M S Silva; Juliana Ferreira Vasques; Paulo Henrique Rosado-de-Castro; Bianca Gutfilen; Valéria do M N Cunha; Aline G M Fraga; Patrícia M R E Silva; Marco Aurélio Martins; Tatiana Paula Teixeira Ferreira; Rosalia Mendes-Otero; Margarete M Trachez; Roberto T Sudo; Gisele Zapata-Sudo Journal: Front Pharmacol Date: 2018-12-06 Impact factor: 5.810
Authors: Michael L Risner; Silvia Pasini; Xitiz Chamling; Nolan R McGrady; Jeffrey L Goldberg; Donald J Zack; David J Calkins Journal: Transl Vis Sci Technol Date: 2021-08-12 Impact factor: 3.048
Authors: Christina Brown; Patrina Agosta; Christina McKee; Keegan Walker; Matteo Mazzella; Ali Alamri; David Svinarich; G Rasul Chaudhry Journal: Stem Cell Res Ther Date: 2022-04-08 Impact factor: 6.832